The New Zealand Herald10d
Daratumumab: Rotorua cancer survivor Tove Jensen-Munroe calls for drug funding
Jensen-Munroe relapsed in 2023 and was told unfunded, $220,000-a-year drug daratumumab was her “best option”. Unable to ...
DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight
DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...
Monthly Prescribing Reference4y
Darzalex Faspro
Daratumumab, hyaluronidase-fihj ... 8 [8 doses], every 2 weeks at Weeks 9–16 [4 doses]); stop for high dose chemotherapy and ASCT; (consolidation phase: re-initiate every 2 weeks at Weeks ...
Hosted on MSN10mon
Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset
Investigators will have a choice of standard of care regimens such as: pomalidomide, bortezomib, and dexamethasone; daratumumab ... followed by lymphodepleting chemotherapy and a single infusion ...
National Institute for Health and Care Excellence10d
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable ID6249
Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when ...
Morningstar1mon
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
Morningstar brands and products Company Portfolio ...